News, perspectives, and milestones from Alifarc.
Alifarc establishes entities in the UK, Germany, and Nigeria.
Areas of business span pharmaceuticals, bioengineering, and biotechnology.
Less than 1% of vaccines used in Africa were manufactured on the continent before COVID. The policy environment has materially changed. We summarise what 2026 looks like for credible operators.
Most pharmaceutical companies treat bioengineering as a service they procure from CROs and CDMOs. We argue the case for owning it upstream.
The phrase is a cliché in pharmaceutical marketing. The competitive advantage Alifarc was incorporated to pursue is more specific.
Be the first to know.
Press releases, scientific publications, partnership announcements, and investor updates. We email only when there is something material to communicate.
Thank you. You're on the list. We'll be in touch when there's something material to share.
Something went wrong. Please email press@alifarc.com.
For journalists
For interview requests, statements, or background on Alifarc's formation, operating entities, and areas of business.
press@alifarc.comLogos & brand assets
Approved logo lockups, brand colours, and a one-page company backgrounder. For use in coverage and partnership announcements.
Request the kitFor partners & capital
For institutional partnerships, scientific collaborations, and investment inquiries, including pre-launch data room access.
Investor relations